Blood Res 2018; 53(1): 92-94
A rare variant of t(17;19) in a case of Philadelphia positive adult acute lymphoblastic leukemia presenting with disseminated intravascular coagulation
Moeinadin Safavi1,2,3*, Akbar Safaei1, and Mahnaz Lotfi4

1Department of Molecular Pathology and Cytogenetic, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

2Department of Molecular Pathology and Cytogenetic, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.

3Department of Pathology, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran.

4Department of Hemato-Oncology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

Correspondence to: Moeinadin Safavi. Department of Molecular Pathology and Cytogenetics, School of Medicine, Shiraz University of Medical Sciences, Zand Street, Shiraz, Iran.,
Received: June 16, 2017; Revised: August 26, 2017; Accepted: October 11, 2017; Published online: March 31, 2018.
© The Korean Journal of Hematology. All rights reserved.


TO THE EDITOR: In acute lymphoblastic leukemia, t(9;22) occurs more commonly in adults (25–30%) than in children (3%) and its incidence increases exponentially with age [1]. This translocation confers a poor prognosis to patients and results in high white blood cell count in addition to high incidence of central nervous system involvement and splenomegaly. Additional cytogenetic aberrations occur in 60% of cases of Philadelphia positive adult acute lymphoblastic leukemia, of which monosomy 7 and 9p abnormalities are considered to be the most common [2].

On the other hand, t(17;19)(q22;p13) is a very rare translocation in acute lymphoblastic leukemia that is associated with an extremely poor prognosis. Coexistence of t(17;19)(q22;p13) with Philadelphia chromosome has only been reported once in the literature [3].


A 41-year-old man was admitted to hospital due to bone pain and abdominal discomfort. Pallor and splenomegaly were the only two abnormal findings on physical examination. Laboratory tests showed prominent leukocytosis, anemia and thrombocytopenia (white blood cell count=170,000/µL, hemoglobin=9.2 g/dL, platelet count= 30,000/µL). Flow cytometry of bone marrow aspiration revealed 80% blast cells with B cell precursor phenotype expressing HLA-DR, CD19, CD10, CD22, tdt, CD20. Bone marrow cytogenetic study with Giemsa banding method exhibited 45XY t(9;22) (q34;q11) de(3) der(9) t(3;9)(q11;q13) del3(q10) t(17;19)(q11;p13) (Fig. 1). Reverse transcription polymerase chain reaction was performed on a bone marrow specimen which also revealed m-bcr-abl1 fusion gene (p 190).

During hospitalization, the patient had an episode of epistaxis and his coagulation tests showed prolonged prothrombin time (PT=19.2 sec, normal range, 11–13 sec), partial thromboplastin time (PTT=42.5 sec, normal range, 25–35 sec) and low fibrinogen level (fibrinogen=92 mg/dL, normal range, 200–400 mg/dL). Thus, he underwent treatment with fresh frozen plasma till the symptoms resolved and the fibrinogen level reached beyond 100 mg/dL. He also received induction chemotherapy with Hyper CVAD chemotherapy regimen including cycles A and B. During cycle A, he took 1) cyclophosphamide with Mesna 500 mg IV on the first 3 days, 2) vincristine 2 mg IV on days 4 and 11, 3) adryamycin 50 mg on day 4, and 4) dexamethasone 40 mg on days 1 to 4 and 11 to 14. Three weeks later cycle B was initiated with the following combination: 1) methotrexate IV infusion 1,600 mg on the first day, 2) folinic acid 30 mg every 6 hours for 8 doses, 3) cytarabine 3,000 mg every 12 hours for 4 doses on 2nd and 3rd days, and 3) methylprednisolone 30 mg twice daily for 6 doses on days 1, 2 and 3. Imatinib (600 mg daily) was also added to his regimen after the detection of Philadelphia chromosome. Meanwhile, the patient received 12 mg intrathecal methotrexate weekly. Unfortunately, the patient's peripheral smear showed prominent leukocytosis (white blood cell count=140,000/µL) with 80% blast cells after completion of hyper-CVAD regimen (four courses of cycle A and B). Then he became candidate for bone marrow transplantation after salvage chemotherapy but he refused to receive salvage chemotherapy regimen. Therefore, there was no remedy but to continue treatment with 6-mercaptopurine (50 mg three times daily), methotrexate (15 mg weekly), vincristine (2 mg monthly) and another tyrosine kinase inhibitor, nilotinib (400 mg daily). Subsequent peripheral blood smear showed no blast cells and complete blood count yielded the following: white blood cells=2,500/µL, hemoglobin=10 g/dL and platelets=25,000/µL.


The Philadelphia chromosome was the first chromosomal aberration found to be associated with malignancy [4]. In fact, it is a diminutive chromosome 22 derived from t(9;22)(q34;q11). This translocation can result in three differently sized fusion products: p190, p210 and rarely p230. This fusion gene has a tyrosine kinase activity and occurs in chronic myelogenous leukemia, acute biphenotypic leukemia, and acute lymphoblastic leukemia. It has recently been discovered that an intragenic deletion of the IKZF1 gene discriminates Philadelphia positive acute lymphoblastic leukemia patients from other t(9;22)(q34;q11) cases [5]. Additional chromosome aberrations are found in 40–86% of Philadelphia positive acute lymphoblastic leukemia cases, of which hyperdiploid karyotype, monosomy 7 and 9p abnormalities are the most common [26]. The incidence of t(9;22)(q34;q11) increases exponentially with age in acute lymphoblastic leukemia patients from 2% in children to 20–40% in adults. This chromosomal abnormality leads to leukocytosis, splenomegaly and central nervous system involvement. Dismal prognosis of this translocation has been improved after the advent of tyrosine kinase inhibitors [78].

t(17;19)(q22;p13) is an extremely rare translocation with an estimated incidence of 0.1% [4]. Among 9,000 acute lymphoblastic leukemia trial patients in the Leukemia Research Cytogenetic Group Survey, only 9 had t(17;19) (q22;p13). Their ages ranged from 5 to 18 years with a median age of 13 years. Acute lymphoblastic leukemia patients had a B-cell precursor phenotype and none of them had remarkable leukocytosis (50×109/L) [9]. It is supposed to be a variant of t(1;19)(q23;p13) and results in fusion of the HLF gene to TCF3 [10]. At the molecular level, there are two different breakpoint positions for this translocation. In type 1, chimeric oncoprotein arises from breakpoint within intron 13 of TCF3 and intron 3 HLF. This type of translocation is associated with disseminated intravascular coagulation. The pathogenesis of hemostatic system activation in acute leukemia is probably due to tumor cell procoagulant activities, fibrinolytic properties and cytokine release [1112]. In type 2, breakpoints in intron 12 of TCF3 and intron 3 of HLF rearrange and make fusion oncoprotein which is associated with hypercalcemia via parathyroid hormone related protein mediation [12]. This case revealed a different breakpoint on the long arm of chromosome 17 in q11 instead of its usual site q22 and seems to be a very rare type of t(17;19) which has been reported once in a case of acute lymphoblastic lymphoma [13].

In a recent review of the literature, 21 cases with t(17;19)(q22;p13) were reported and their clinical presentation and outcome were evaluated. They were all children and teenagers with ages ranging from 3 to 16 years, and there was a slight female predominance. Nine cases showed evidence of disseminated intravascular coagulation at diagnosis or during the course of the disease. Twelve cases also demonstrated hypercalcemia in their laboratory tests. Almost all of them died due to relapse of leukemia or post-chemotherapy infection [14].

Our case had some features of both t(9;22) and t(17;19). The present case was an adult who had remarkable leukocytosis and splenomegaly which are all common in Philadelphia positive acute lymphoblastic leukemia and rare in t(17;19). On the other hand, he also had disseminated intravascular coagulation, which is a feature of t(17;19). We reviewed the literature and found only one case of Philadelphia positive adult lymphoblastic leukemia with t(17;19) whose clinical presentation was relatively similar to ours. That case was a 44-year-old woman with weakness, splenomegaly and leukocytosis [3]. These findings show that coincidence of t(17;19) and t(9;22) tends to be seen in adults rather than children and may be associated with remarkable leukocytosis and splenomegaly in addition to disseminated intravascular coagulation or hypercalcemia. Glover et al. [15] exhibited in vitro susceptibility of leukemic blasts from a patient to tyrosine kinase inhibitors. However, its effectiveness is not improved in vivo due to the rarity of cases with t(17;19).

Authors' Disclosures of Potential Conflicts of Interest

No potential conflicts of interest relevant to this article were reported.

Fig. 1.

Bone marrow karyotype exhibited t(17;19)(q11;p13) in addition to Philadelphia chromosome and unbalanced translocation between chromosomes 3 and 9.

  1. Secker-Walker, LM, Craig, JM, Hawkins, JM, Hoffbrand, AV. Philadelphia positive acute lymphoblastic leukemia in adults: age distribution, BCR breakpoint and prognostic significance. Leukemia, 1991;5;196-199.
  2. Ko, BS, Tang, JL, Lee, FY, et al. Additional chromosomal abnormalities and variability of BCR breakpoints in Philadelphia chromosome/ BCR-ABL-positive acute lymphoblastic leukemia in Taiwan. Am J Hematol, 2002;71;291-299.
  3. Specchia, G, Albano, F, Anelli, L, et al. Molecular cytogenetics characterization of a novel translocation involving chromosomes 17 and 19 in a Ph+ adult acute lymphoblastic leukaemia. Br J Haematol, 2002;119;488-491.
  4. Moorman, AV. The clinical relevance of chromosomal and genomic abnormalities in B-cell precursor acute lymphoblastic leukaemia. Blood Rev, 2012;26;123-135.
  5. Mullighan, CG, Miller, CB, Radtke, I, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature, 2008;453;110-114.
  6. Rieder, H, Ludwig, WD, Gassmann, W, et al. Prognostic significance of additional chromosome abnormalities in adult patients with Philadelphia chromosome positive acute lymphoblastic leukaemia. Br J Haematol, 1996;95;678-691.
  7. Druker, BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood, 2008;112;4808-4817.
  8. Schultz, KR, Bowman, WP, Aledo, A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol, 2009;27;5175-5181.
  9. Harrison, CJ, Martineau, M, Secker-Walker, LM. The Leukaemia Research Fund/United Kingdom Cancer Cytogenetics Group Karyotype Database in acute lymphoblastic leukaemia: a valuable resource for patient management. Br J Haematol, 2001;113;3-10.
  10. Inaba, T, Roberts, WM, Shapiro, LH, et al. Fusion of the leucine zipper gene HLF to the E2A gene in human acute B-lineage leukemia. Science, 1992;257;531-534.
  11. Barbui, T, Falanga, A. Disseminated intravascular coagulation in acute leukemia. Semin Thromb Hemost, 2001;27;593.
  12. Hunger, SP, Devaraj, PE, Foroni, L, Secker-Walker, LM, Cleary, ML. Two types of genomic rearrangements create alternative E2A-HLF fusion proteins in t(17;19)-ALL. Blood, 1994;83;2970-2977.
  13. Arana-Trejo, RM, Cervantes-Peredo, A, Rozen, E, Kassack, JJ, Gutiérrez, M, Kofman-Alfaro, S. Cytogenetic study of 22 adults and 3 children with acute lymphoblastic leukemia. Rev Invest Clin, 1993;45;43-48.
  14. Minson, KA, Prasad, P, Vear, S, et al. t(17;19) in children with acute lymphocytic leukemia: a report of 3 cases and a review of the literature. Case Rep Hematol, 2013;2013;563291.
  15. Glover, JM, Loriaux, M, Tyner, JW, Druker, BJ, Chang, BH. In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia. Pediatr Blood Cancer, 2012;59;576-579.


This Article

Current Issue


Indexed/Covered by

Today : 111  /
Total : 98,874